Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 107.33B +73.6% |
| Revenue (ttm) | 54.78B +4.4% |
| Net Income | 4.94B |
| EPS | 4.23 |
| Shares Out | n/a |
| PE Ratio | 21.72 |
| Forward PE | 13.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,061,041 |
| Open | 9,580.00 |
| Previous Close | 9,533.00 |
| Day's Range | 9,396.00 - 9,645.00 |
| 52-Week Range | 5,305.00 - 11,350.00 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande...
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the comp...
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growt...
Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar
Teva (TEVA) Pharmaceuticals and Polpharma Biologics International announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ propo...
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics Interna...
Teva, Polpharma Biologics announce global licensing agreement
Teva (TEVA) Pharmaceuticals International, a subsidiary of Teva, and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Pol...
Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ
Teva (TEVA) Pharmaceutical Industries and Samsung Bioepis announced that the companies have entered into a license and commercialization agreement for OPUVIZ, a biosimilar referencing Eylea, in Canada...
Teva Pharmaceutical Industries Transcript: Study result
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and favorable safety. The antibody's quarterly dosing and efficacy compare well to oral JAKs, and broader development in related diseases is underway.
Teva Pharmaceutical Industries Press release: Study result
Teva Pharmaceutical Industries issued a press release on July 7, 2026, disclosing material business information to investors.
Teva Pharmaceutical Industries Slides: Study result
Teva Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4
Teva (TEVA) announced plans to advance its TEV-‘408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows e...
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and ...
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.
Teva submits NDA for Ecopipam to FDA
The company states: “Teva (TEVA) Pharmaceutical announced the submission of a New Drug Application to the U.S. Food and Drug Administration for ecopipam, a first-in-class investigational therapy for t...
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug A...
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quar...
Jefferies continues to like Teva after recent pullback
Noting that Teva (TEVA) has underperformed the last two weeks, Jefferies analyst Dennis Ding explained that a “big part of the weakness is due to macro,” but also says it…
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology comp...
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strengthening it...
Teva put volume heavy and directionally bearish
Bearish flow noted in Teva (TEVA) with 4,549 puts trading, or 3x expected. Most active are 6/12 weekly 33.5 puts and Sep-26 40 calls, with total volume in those strikes…
Teva presents positive long-term study data for Austedo
Teva (TEVA) announced new data highlighting symptom improvement from treatment with Austedo and Austedo XR in patients with tardive dyskinesia. Findings from the real-world IMPACT-TD study evaluated p...
Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data t...
Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a disciplined growth strategy centered on innovation, generics expansion, and capital allocation, with major product launches and pipeline readouts expected through 2028. The company’s transformation into a biopharma leader is reinforced by robust execution, undervalued assets, and a strong outlook for long-term value creation.
Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets
Teva (TEVA) Pharmaceuticals announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease ch...